Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 2, 2015, Pages 197-207

  Chung, Doo Ryeon ^a   Huh, Kyungmin ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Armed Forces Capital Hospital   (South Korea)

Author keywords

anti bacterial agents; bacterial drug resistance; bacterial pneumonia; coinfection; linezolid; vancomycin

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CLINDAMYCIN; CYTOKINE; DAPTOMYCIN; GAMMA INTERFERON; IMMUNOGLOBULIN; LINEZOLID; TEICOPLANIN; TUMOR NECROSIS FACTOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; HUMAN; INFECTION CONTROL; INFLUENZA A (H1N1); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOLECULAR DIAGNOSIS; NONHUMAN; PANDEMIC INFLUENZA; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SECONDARY INFECTION; ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED INFECTION; COMPLICATION; DRUG EFFECTS; EARLY DIAGNOSIS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; PANDEMIC; PHYSIOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; EARLY DIAGNOSIS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PANDEMICS; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL; VANCOMYCIN;

EID: 84937149339     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.999668     Document Type: Review

References (115)

1. World Health Organization, Fact sheets, Influenza (seasonal). 2014. Available from: www.who.int/mediacentre/factsheets/fs211/en/[Accessed on 01 August 2014]
2. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59(33):1057-62
3. Xu J, Kochanek KD, Tejada-Vera B. Deaths: preliminary data for 2007. Natl Vital Stat Rep 2009;58(1):1-52
4. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. Bull Hist Med 2002;76(1):105-15
5. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12(9):687-95
6. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008;198(7): 962-70
7. Robertson L, Caley JP, Moore J. Importance of Staphylococcus aureus in pneumonia in the 1957 epidemic of influenza A. Lancet 1958;2(7040):233-6
8. Louria DB, Blumenfeld HL, Ellis JT, et al. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959;38(1 Part 2): 213-65
9. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12(6):894-9
10. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 2008;122(4):805-11
11. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 2009;64(3):441-6
12. Witte W, Strommenger B, Cuny C, et al. Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J Antimicrob Chemother 2007;60(6):1258-63
13. Huang YC, Hwang KP, Chen PY, et al. Prevalence of methicillin-resistant Staphylococcus aureus nasal colonization among Taiwanese children in 2005 and 2006. J Clin Microbiol 2007;45(12):3992-5
14. Nimmo GR, Coombs GW. Community-associated methicillin-resistant Staphylococcus aureus (MRSA) in Australia. Int J Antimicrob Agents 2008;31(5):401-10
15. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40(1):100-7
16. Podewils LJ, Liedtke LA, McDonald LC, et al. A national survey of severe influenza-associated complications among children and adults, 2003-2004. Clin Infect Dis 2005;40(11):1693-6
17. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56(14):325-9
18. Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009;53(3):358-65
19. Peebles PJ, Dhara R, Brammer L, et al. Influenza-associated mortality among children-United States: 2007-2008. Influenza Other Respir Viruses 2011;5(1): 25-31
20. Centers for Disease Control and Prevention. Update: influenza activity-United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010;59(29):901-8
21. Centers for Disease Control and Prevention. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009;58(38): 1071-4
22. Fowlkes AL, Arguin P, Biggerstaff MS, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin Infect Dis 2011;52(Suppl 1):S60-8
23. Hayashi Y, Vaska VL, Baba H, et al. Influenza-associated bacterial pathogens in patients with 2009 influenza A (H1N1) infection: impact of community-associated methicillin-resistant Staphylococcus aureus in Queensland, Australia. Intern Med J 2012;42(7):755-60
24. Murray RJ, Robinson JO, White JN, et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenza virus and methicillin resistant Staphylococcus aureus co-infection. PLoS One 2010;5(1): e8705
25. Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40(5):1487-98
26. Muscedere J, Ofner M, Kumar A, et al. The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A (H1N1) infection. Chest 2013;144(1):39-47
27. Martín-Loeches I, Sanchez-Corral A, Diaz E, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza a(h1n1) virus. Chest 2011;139(3):555-62
28. Sohn KM, Chung DR, Baek JY, et al. Post-influenza pneumonia caused by the USA300 community-associated methicillinresistant Staphylococcus aureus in Korea. J Korean Med Sci 2012;27(3):313-16
29. Randolph AG, Vaughn F, Sullivan R, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics 2011;128(6): e1450-8
30. Cox CM, Blanton L, Dhara R, et al. 2009 Pandemic Influenza A (H1N1) deaths among children-United States, 2009-2010. Clin Infect Dis 2011;52(Suppl 1): S69-74
31. Kallen AJ, Reed C, Patton M, et al. Staphylococcus aureus community-onset pneumonia in patients admitted to children's hospitals during autumn and winter of 2006-2007. Epidemiol Infect 2010;138(5):666-72
32. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 2009;34(5):1148-58
33. Geng W, Yang Y, Wu D, et al. Community-acquired, methicillin-resistant Staphylococcus aureus isolated from children with community-onset pneumonia in China. Pediatr Pulmonol 2010;45(4): 387-94
34. MacCallum WG. Pathological anatomy of pneumonia associated with influenza. Johns Hopkins Hosp Rep 1921;20:149-249
35. Fainstein V, Musher DM, Cate TR. Bacterial adherence to pharyngeal cells during viral infection. J Infect Dis 1980; 141(2):172-6
36. Davison VE, Sanford BA. Adherence of staphylococcus aureus to influenza A virus-infected Madin-Darby canine kidney cell cultures. Infect Immun 1981;32(1): 118-26
37. Davison VE, Sanford BA. Factors influencing adherence of Staphylococcus aureus to influenza A virus-infected cell cultures. Infect Immun 1982;37(3):946-55
38. Sanford BA, Davison VE, Ramsay MA. Staphylococcus aureus adherence to influenza A virus-infected and control cell cultures: evidence for multiple adhesins. Proc Soc Exp Biol Med 1986;181(1): 104-11
39. Nugent KM, Pesanti EL. Tracheal function during influenza infections. Infect Immun 1983;42(3):1102-8
40. Sanford BA, Ramsay MA. Bacterial adherence to the upper respiratory tract of ferrets infected with influenza A virus. Proc Soc Exp Biol Med 1987;185(2):120-8
41. Plotkowski MC, Puchelle E, Beck G, et al. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986;134(5):1040-4
42. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003;187(6): 1000-9
43. Chockalingam AK, Hickman D, Pena L, et al. Deletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia. J Virol 2012;86(7):3564-73
44. Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377(6548):435-8
45. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 2006;290(1):L194-9
46. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002;186(3): 341-50
47. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following influenza. J Immunol 2013;191(5):2047-52
48. Larson HE, Parry RP, Gilchrist C, et al. Influenza viruses and staphylococci in vitro: some interactions with polymorphonuclear leucocytes and epithelial cells. Br J Exp Pathol 1977;58(3):281-8
49. Gardner ID, Kung TM. Histopathological changes in the lungs of influenza-infected mice superinfected with Staphylococcus aureus. Br J Exp Pathol 1980;61(4):415-20
50. Abramson JS, Lewis JC, Lyles DS, et al. Inhibition of neutrophil lysosome-phagosome fusion associated with influenza virus infection in vitro. Role in depressed bactericidal activity. J Clin Invest 1982;69(6):1393-7
51. Abramson JS, Parce JW, Lewis JC, et al. Characterization of the effect of influenza virus on polymorphonuclear leukocyte membrane responses. Blood 1984;64(1): 131-8
52. Jakab GJ. Immune impairment of alveolar macrophage phagocytosis during influenza virus pneumonia. Am Rev Respir Dis 1982; 126(5):778-82
53. Nugent KM, Pesanti EL. Effect of influenza infection on the phagocytic and bactericidal activities of pulmonary macrophages. Infect Immun 1979;26(2):651-7
54. Nugent KM, Pesanti EL. Staphylococcal clearance and pulmonary macrophage function during influenza infection. Infect Immun 1982;38(3):1256-62
55. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008;14(5): 558-64
56. Hang do TT, Choi EJ, Song JY, et al. Differential effect of prior influenza infection on alveolar macrophage phagocytosis of Staphylococcus aureus and Escherichia coli: involvement of interferon-gamma production. Microbiol Immunol 2011;55(11):751-9
57. Zhang WJ, Sarawar S, Nguyen P, et al. Lethal synergism between influenza infection and staphylococcal enterotoxin B in mice. J Immunol 1996;157(11):5049-60
58. Lee MH, Arrecubieta C, Martin FJ, et al. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 2010; 201(4):508-15
59. Braun LE, Sutter DE, Eichelberger MC, et al. Co-infection of the cotton rat (Sigmodon hispidus) with Staphylococcus aureus and influenza A virus results in synergistic disease. Microb Pathog 2007; 43(5-6):208-16
60. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004;172(12):7603-9
61. McKinstry KK, Strutt TM, Buck A, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009;182(12): 7353-63
62. Small CL, Shaler CR, McCormick S, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol 2010; 184(4):2048-56
63. Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011;186(3):1666-74
64. Robinson KM, Choi SM, McHugh KJ, et al. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1beta production in mice. J Immunol 2013; 191(10):5153-9
65. Tian X, Xu F, Lung WY, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS One 2012;7(9):e41879
66. Hall MW, Geyer SM, Guo CY, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med 2013; 41(1):224-36
67. Sun K, Metzger DW. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol 2014;192(7):3301-7
68. Tashiro M, Ciborowski P, Klenk HD, et al. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987;325(6104):536-7
69. Tashiro M, Ciborowski P, Reinacher M, et al. Synergistic role of staphylococcal proteases in the induction of influenza virus pathogenicity. Virology 1987;157(2):421-30
70. Scheiblauer H, Reinacher M, Tashiro M, Rott R. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. J Infect Dis 1992; 166(4):783-91
71. Okayama Y, Yano H, Nojima Y, et al. Influence of prior pandemic A(H1N1) 2009 virus infection on invasion of MDCK cells by community-associated methicillinresistant Staphylococcus aureus. J Infect Chemother 2014;20(1):71-3
72. McHugh KJ, Mandalapu S, Kolls JK, et al. A novel outbred mouse model of 2009 pandemic influenza and bacterial co-infection severity. PLoS One 2013;8(12): e82865
73. Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009;9(6): 384-92
74. Dean N. Methicillin-resistant Staphylococcus aureus in communityacquired and health care-associated pneumonia: incidence, diagnosis, and treatment options. Hosp Pract (1995) 2010; 38(1):7-15
75. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008;31(3):625-32
76. Anevlavis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009;59(2):83-9
77. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
78. Ince J, McNally A. Development of rapid, automated diagnostics for infectious disease: advances and challenges. Expert Rev Med Devices 2009;6(6):641-51
79. Wolk DM, Struelens MJ, Pancholi P, et al. Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol 2009;47(3):823-6
80. Peterson LR. Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus. Clin Infect Dis 2011;52(Suppl 4):S361-6
81. Lu JJ, Tsai FJ, Ho CM, et al. Peptide biomarker discovery for identification of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus strains by MALDI-TOF. Anal Chem 2012;84(13):5685-92
82. Josten M, Reif M, Szekat C, et al. Analysis of the matrix-assisted laser desorption ionization-time of flight mass spectrum of Staphylococcus aureus identifies mutations that allow differentiation of the main clonal lineages. J Clin Microbiol 2013;51(6): 1809-17
83. Romero-Gomez MP, Munoz-Velez M, Gomez-Gil R, Mingorance J. Evaluation of combined use of MALDI-TOF and Xpert ((R)) MRSA/SA BC assay for the direct detection of methicillin resistance in Staphylococcus aureus from positive blood culture bottles. J Infect 2013;67(1):91-2
84. Clerc O, Prod'hom G, Senn L, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2014;20(4):355-60
85. Geisel R, Schmitz FJ, Thomas L, et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999;43(6):846-8
86. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350(9092):1670-3
87. Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 2013;17(2): e93-e100
88. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
89. Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49(3):325-7
90. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43(13):925-42
91. Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 2014;59(5):666-75
92. Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011;52(8):969-74
93. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57(2):734-44
94. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin Infect Dis 2009;49(4):507-14
95. Wunderink RG, Cammarata SK, Oliphant TH, Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25(3):980-92
96. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54(5):621-9
97. Wolff M, Mourvillier B. Linezolid for the treatment of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2012;55(1):160-1
98. Lahey T. Questionable superiority of linezolid for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: watch where you step. Clin Infect Dis 2012;55(1):159-60
99. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53(10):4069-79
100. Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010(6):CD007022
101. Yoon YK, Park DW, Sohn JW, et al. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillinresistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2014;58(1): 317-24
102. Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 2014;58(Suppl 1):S20-7
103. Wenzel RP, Bearman G, Edmond MB. Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control. Int J Antimicrob Agents 2007;30(3):210-12
104. Karlstrom A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009;199(3):311-19
105. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S378-85
106. Metersky ML, Masterton RG, Lode H, et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012;16(5):e321-31
107. Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther 2013;11(10):1041-51
108. Ghoneim HE, McCullers JA. Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis 2014;209(9):1459-68
109. Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004;189(2):346-53
110. van den Akker EL, Nouwen JL, Melles DC, et al. Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J Infect Dis 2006;194(6): 814-18
111. Emonts M, Uitterlinden AG, Nouwen JL, et al. Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J Infect Dis 2008;197(9):1244-53
112. Ruimy R, Angebault C, Djossou F, et al. Are host genetics the predominant determinant of persistent nasal Staphylococcus aureus carriage in humans? J Infect Dis 2010;202(6):924-34
113. von Kockritz-Blickwede M, Rohde M, Oehmcke S, et al. Immunological mechanisms underlying the genetic predisposition to severe Staphylococcus aureus infection in the mouse model. Am J Pathol 2008;173(6):1657-68
114. Ferdinands JM, Denison AM, Dowling NF, et al. A pilot study of host genetic variants associated with influenza-associated deaths among children and young adults. Emerg Infect Dis 2011;17(12):2294-302
115. Toufeer M, Bonnefont CM, Foulon E, et al. Gene expression profiling of dendritic cells reveals important mechanisms associated with predisposition to Staphylococcus infections. PLoS One 2011; 6(8):e22147